171 related articles for article (PubMed ID: 36008864)
1. Achaete-scute complex-like 2 regulated inflammatory mechanism through Toll-like receptor 4 activating in stomach adenocarcinoma.
Zheng E; Cai Z; Li W; Ni C; Fang Q
World J Surg Oncol; 2022 Aug; 20(1):266. PubMed ID: 36008864
[TBL] [Abstract][Full Text] [Related]
2. CDCA7-regulated inflammatory mechanism through TLR4/NF-κB signaling pathway in stomach adenocarcinoma.
Guo Y; Zhou K; Zhuang X; Li J; Shen X
Biofactors; 2021 Sep; 47(5):865-878. PubMed ID: 34339079
[TBL] [Abstract][Full Text] [Related]
3. Differential Expression of the
Hu J; Xu J; Feng X; Li Y; Hua F; Xu G
Front Cell Dev Biol; 2021; 9():700661. PubMed ID: 34631699
[TBL] [Abstract][Full Text] [Related]
4. The Potential Role of IL1RAP on Tumor Microenvironment-Related Inflammatory Factors in Stomach Adenocarcinoma.
Lv Q; Xia Q; Li A; Wang Z
Technol Cancer Res Treat; 2021; 20():1533033821995282. PubMed ID: 33602046
[TBL] [Abstract][Full Text] [Related]
5. Achaete-scute complex homologue 2 accelerates the development of Sjögren's syndrome-like disease in the NOD/ShiLtJ mouse.
Kim SM; Kwon JE; Park JS; Seo HB; Jung KA; Moon YM; Lee J; Kwok SK; Cho ML; Park SH
Immunol Lett; 2017 Oct; 190():26-33. PubMed ID: 28728856
[TBL] [Abstract][Full Text] [Related]
6. Achaete scute-like 2 suppresses CDX2 expression and inhibits intestinal neoplastic epithelial cell differentiation.
Shang Y; Pan Q; Chen L; Ye J; Zhong X; Li X; Meng L; Guo J; Tian Y; He Y; Chen W; Peng Z; Wang R
Oncotarget; 2015 Oct; 6(31):30993-1006. PubMed ID: 26307678
[TBL] [Abstract][Full Text] [Related]
7. Systematic analysis of the achaete-scute complex-like gene signature in clinical cancer patients.
Wang CY; Shahi P; Huang JT; Phan NN; Sun Z; Lin YC; Lai MD; Werb Z
Mol Clin Oncol; 2017 Jan; 6(1):7-18. PubMed ID: 28123722
[TBL] [Abstract][Full Text] [Related]
8. WGCNA identification of TLR7 as a novel diagnostic biomarker, progression and prognostic indicator, and immunotherapeutic target for stomach adenocarcinoma.
Yuan Q; Zhou Q; Ren J; Wang G; Yin C; Shang D; Xia S
Cancer Med; 2021 Jun; 10(12):4004-4016. PubMed ID: 33982398
[TBL] [Abstract][Full Text] [Related]
9. ASCL2 Affects the Efficacy of Immunotherapy in Colon Adenocarcinoma Based on Single-Cell RNA Sequencing Analysis.
Wu L; Sun S; Qu F; Liu X; Sun M; Pan Y; Zheng Y; Su G
Front Immunol; 2022; 13():829640. PubMed ID: 35774798
[TBL] [Abstract][Full Text] [Related]
10. Aberrant upregulation of ASCL2 by promoter demethylation promotes the growth and resistance to 5-fluorouracil of gastric cancer cells.
Kwon OH; Park JL; Baek SJ; Noh SM; Song KS; Kim SY; Kim YS
Cancer Sci; 2013 Mar; 104(3):391-7. PubMed ID: 23181270
[TBL] [Abstract][Full Text] [Related]
11. WiNTRLINC1/ASCL2/c-Myc Axis Characteristics of Colon Cancer with Differentiated Histology at Young Onset and Essential for Cell Viability.
Yokota K; Tanaka Y; Harada H; Kaida T; Nakamoto S; Soeno T; Fujiyama Y; Yokota M; Kojo K; Miura H; Yamanashi T; Sato T; Nakamura T; Watanabe M; Yamashita K
Ann Surg Oncol; 2019 Dec; 26(13):4826-4834. PubMed ID: 31549316
[TBL] [Abstract][Full Text] [Related]
12. Ascl2 facilitates IL-10 production in Th17 cells to restrain their pathogenicity in inflammatory bowel disease.
Yi Q; Wang J; Song Y; Guo Z; Lei S; Yang X; Li L; Gao C; Zhou Z
Biochem Biophys Res Commun; 2019 Mar; 510(3):435-441. PubMed ID: 30722992
[TBL] [Abstract][Full Text] [Related]
13. Transcription factor achaete-scute homologue 2 initiates follicular T-helper-cell development.
Liu X; Chen X; Zhong B; Wang A; Wang X; Chu F; Nurieva RI; Yan X; Chen P; van der Flier LG; Nakatsukasa H; Neelapu SS; Chen W; Clevers H; Tian Q; Qi H; Wei L; Dong C
Nature; 2014 Mar; 507(7493):513-8. PubMed ID: 24463518
[TBL] [Abstract][Full Text] [Related]
14. Astragalus mongholicus regulate the Toll-like-receptor 4 meditated signal transduction of dendritic cells to restrain stomach cancer cells.
Tian Y; Li X; Li H; Lu Q; Sun G; Chen H
Afr J Tradit Complement Altern Med; 2014; 11(3):92-6. PubMed ID: 25371568
[TBL] [Abstract][Full Text] [Related]
15. Achaete-scute family bHLH transcription factor 2 activation promotes hepatoblastoma progression.
Kato Y; Fukazawa T; Tanimoto K; Kanawa M; Kojima M; Saeki I; Kurihara S; Touge R; Hirohashi N; Okada S; Hiyama E
Cancer Sci; 2024 Mar; 115(3):847-858. PubMed ID: 38183173
[TBL] [Abstract][Full Text] [Related]
16. Toll-like receptor 3 is a potential prognosis marker and associated with immune infiltration in stomach adenocarcinoma.
Huang Z; He A; Wang J; Lu H; Xu X; Zhang R; Liao W; Feng Q; Wu L
Cancer Biomark; 2022; 34(1):77-93. PubMed ID: 34657879
[TBL] [Abstract][Full Text] [Related]
17. SMYD3 controls a Wnt-responsive epigenetic switch for ASCL2 activation and cancer stem cell maintenance.
Wang T; Wu H; Liu S; Lei Z; Qin Z; Wen L; Liu K; Wang X; Guo Y; Liu Q; Liu L; Wang J; Lin L; Mao C; Zhu X; Xiao H; Bian X; Chen D; Xu C; Wang B
Cancer Lett; 2018 Aug; 430():11-24. PubMed ID: 29746925
[TBL] [Abstract][Full Text] [Related]
18. DPEP1 promotes drug resistance in colon cancer cells by forming a positive feedback loop with ASCL2.
Zeng C; Qi G; Shen Y; Li W; Zhu Q; Yang C; Deng J; Lu W; Liu Q; Jin J
Cancer Med; 2023 Jan; 12(1):412-424. PubMed ID: 35670012
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-200 (miR-200) cluster regulation by achaete scute-like 2 (Ascl2): impact on the epithelial-mesenchymal transition in colon cancer cells.
Tian Y; Pan Q; Shang Y; Zhu R; Ye J; Liu Y; Zhong X; Li S; He Y; Chen L; Zhao J; Chen W; Peng Z; Wang R
J Biol Chem; 2014 Dec; 289(52):36101-15. PubMed ID: 25371200
[TBL] [Abstract][Full Text] [Related]
20. Achaete-scute like 2 (ascl2) is a target of Wnt signalling and is upregulated in intestinal neoplasia.
Jubb AM; Chalasani S; Frantz GD; Smits R; Grabsch HI; Kavi V; Maughan NJ; Hillan KJ; Quirke P; Koeppen H
Oncogene; 2006 Jun; 25(24):3445-57. PubMed ID: 16568095
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
